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Abstract
BACKGROUND—Epigenetic differences exist between trauma-exposed individuals with and 
without posttraumatic stress disorder (PTSD). It is unclear whether these epigenetic differences 
preexist, or arise following, trauma and PTSD onset.
METHODS—In pre- and post-trauma samples from a subset of Detroit Neighborhood Health 
Study participants, DNA methylation (DNAm) was measured at DNMT1, DNMT3A, DNMT3B, 
and DNMT3L. Pre-trauma DNAm differences and changes in DNAm from pre- to post-trauma 
were assessed between and within PTSD cases (n=30) and age-, gender-, and trauma exposure-
matched controls (n=30). Pre-trauma DNAm was tested for association with post-trauma symptom 
severity (PTSS) change. Potential functional consequences of DNAm differences were explored 
via bioinformatic search for putative transcription factor binding sites (TFBS).
RESULTS—DNMT1 DNAm increased following trauma in PTSD cases (p=0.001), but not 
controls (p=0.067). DNMT3A and DNMT3B DNAm increased following trauma in both cases 
(DNMT3A: p=0.009; DNMT3B: p<0.001) and controls (DNMT3A: p=0.002; DNMT3B: 
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p<0.001). In cases only, pre-trauma DNAm was lower at a DNMT3B CpG site that overlaps with a 
TFBS involved in epigenetic regulation (p=0.001); lower pre-trauma DNMT3B DNAm at this site 
was predictive of worsening of PTSS post-trauma (p=0.034). Some effects were attenuated 
following correction for multiple hypothesis testing.
CONCLUSIONS—DNAm among trauma-exposed individuals shows both longitudinal changes 
and preexisting epigenetic states that differentiate individuals who are resilient vs. susceptible to 
PTSD. These distinctive DNAm differences within DNMT loci may contribute to genome-wide 
epigenetic profiles of PTSD.
Keywords
posttraumatic stress disorder; epigenetics; DNA methylation; susceptibility; longitudinal; 
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Introduction
PTSD is a prevalent and debilitating mental health disorder that may arise following 
exposure to a potentially traumatic event (Association, 2013). While the lifetime prevalence 
of traumatic exposure is 50–90%(Kessler et al., 1995), PTSD in the general U.S. population 
is estimated to be only 6.8%(Kessler and Wang, 2008). Although the majority of persons 
exposed to trauma display resiliency (Kessler et al., 1995; Breslau et al., 1998; Acierno et 
al., 2007; Kessler and Wang, 2008), the molecular underpinnings of risk remain poorly 
characterized. The identification of risk markers, and particularly biomarkers, that 
distinguish between persons at high and low risk of developing PTSD following trauma 
exposure has been identified as a priority research goal by the Institute of Medicine 
(Medicine, 2012), Department of Defense(Congressionally Directed Medical Research 
Programs, 2011), and the National Institute of Mental Health (NIMH, 2008). Ideally, the 
ability to identify persons at high risk of developing PTSD would enable providers to target 
evidence-based interventions to high-risk groups(Andrews and Neises, 2012). The 
identification of robust predictive biomarkers may also improve our understanding of the 
pathophysiology of PTSD and lead to more effective pharmacological interventions.
Although much work has been done to identify social and environmental factors that 
contribute to PTSD risk [e.g. (Kulka et al., 1990; Breslau et al., 1991; Brewin et al., 2000; 
Koenen et al., 2003; Breslau et al., 2004; DiGrande et al., 2008; Galea et al., 2008; Kun et 
al., 2009)], the biological undergirding of differential PTSD risk and resiliency remains to 
be more fully elucidated. Twin studies have demonstrated heritability and genetic 
contribution to PTSD risk(True et al., 1993; Koenen et al., 2002; Stein et al., 2002) and 
targeted gene and GWAS approaches have identified both genetic risk loci(Lu et al., 2008; 
Ressler et al., 2011; Chang et al., 2012; Logue et al., 2013) and important gene-by-
environment interactions (Binder et al., 2008; Xie et al., 2010; Uddin et al., 2013) that 
contribute to risk for the disorder; nevertheless, a substantial proportion of biologically 
mediated variance in PTSD risk has yet to be explained.
Epigenetic variability is considered a plausible and increasingly empirically supported 
contributor to the etiology of phenotypes with marked genetic and environmental 
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influences(Meaney, 2010), including certain psychopathologies(Toyokawa et al., 2012). 
Indeed, recent advances have revealed that PTSD risk and resiliency is associated with 
differential epigenetic variation(El-Sayed et al., 2012). Epigenetic mechanisms – including 
histone modifications, non-protein coding RNAs, and, most notably, DNA methylation 
(DNAm) – affect gene expression and cellular phenotype without altering the underlying 
DNA sequence(Feinberg, 2008; Meaney, 2010). DNAm is stably heritable across mitotic 
replications, but is modifiable throughout the life course in response to lived experiences 
and environmental exposures(Bird, 2002). In primordial mammalian germ cells, global 
DNAm is removed (with the exception of imprinted loci)(Reik et al., 2001), with new 
patterns established by de novo methyltransferases DNMT3A, DNMT3B, and DNMT3L 
following fertilization(Bourc’his et al., 2001; Bourc’his and Bestor, 2004; Kaneda et al., 
2004; Kato et al., 2007; Ooi et al., 2007). These reprogrammed DNAm patterns are largely 
maintained throughout mitotic DNA replication by the action of the maintenance 
methyltransferase, DNMT1(Li et al., 1992; Seisenberger et al., 2013).
Although influenced by other variables, global DNAm patterns are largely established and 
maintained by the activity of the DNA methyltransferases, DNMT1, DNMT3A, DNMT3B, 
and DNMT3L(Feng and Fan, 2009). Gene expression evidence suggests that these DNMTs 
may be active throughout the life course(Robertson et al., 1999; Feng et al., 2005; Siegmund 
et al., 2007), including in brain tissue(Goto et al., 1994; Veldic et al., 2004; Feng et al., 
2005) and in association with mental disorders(Veldic et al., 2004; Veldic et al., 2005). In 
addition, protein-level expression of DNMT1(Inano et al., 2000; Veldic et al., 2005) and 
DNMT3A(Feng et al., 2005) has been demonstrated in the mouse and human brain. With 
respect to PTSD, recent work confirms that DNMT activity plays a role in mediating risk for 
PTSD-related phenotypes, including fear conditioning and memory consolidation (Miller 
and Sweatt, 2007; Feng et al., 2010). Together, these findings suggest that DNAm and DNA 
methyltransferases represent promising targets for the identification of epigenetic 
underpinnings of differential PTSD risk and resiliency.
Studies of epigenetic variation have provided important insights into PTSD risk, but have 
been largely limited by cross-sectional analyses of post-trauma samples. Most notably, 
epidemiological cohorts from Detroit(Uddin et al., 2010) and Atlanta(Smith et al., 2011) 
have been the basis of research that has demonstrated cross-sectional differential DNAm 
that distinguishes between trauma-exposed individuals with vs. without PTSD. DNMT3B 
and DNMT3L were among the differentially methylated loci identified in the Detroit 
study(Uddin et al., 2010). More recently, longitudinal DNAm data among PTSD cases and 
controls have been reported, including studies using samples from a cohort of U.S. military 
personnel deployed to Iraq and Afghanistan(Rusiecki et al., 2012; Rusiecki et al., 2013). To 
further elucidate whether differential DNAm between trauma exposed controls and PTSD 
cases represent pre-existing susceptibility/resiliency factors or downstream biomarkers of 
PTSD, additional longitudinal analyses are required. Finally, while the identification of 
epigenetic variation associated with mental health outcomes is important, work must begin 
to test the putative functionality of mental health-associated differential DNAm. For 
example, the identification of transcription factor binding sites (TFBS) that overlap with 
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differentially methylated CpG sites and to which transcription factor binding may be 
disrupted offer one possibility of supporting DNAm functionality(Weaver et al., 2004).
Here, we analyze DNAm from individuals pre- and post-trauma to identify differences that 
characterize individuals who are susceptible vs. resilient to PTSD following trauma. To 
assess potential functional consequences of examined DNAm differences, we then perform a 
bioinformatic search for the presence of putative transcription factor binding sites(Weaver et 
al., 2004). Results from this work suggest that PTSD-relevant DNAm differences in DNMT 




Samples are from a subset of participants from the Detroit Neighborhood Health Study 
(DNHS), a longitudinal, community-representative cohort of adult residents in Detroit, MI. 
The current study draws on peripheral blood samples and survey data obtained at two time 
points were from 60 DNHS participants. Forty-six were female and fourteen male; forty-six 
were African-American and 12 were Caucasian, and 2 were Hispanic. The average age was 
55.1 years. PTSD diagnosis was assessed via structured interview administered via 
telephone(Breslau et al., 1998). PTSD symptoms were assessed in reference to both the 
traumatic event the participant regarded as their worst and one randomly selected traumatic 
event from the remaining traumas the participant experienced. Lifetime PTSD cases met all 
six DSM-IV criteria in reference to either the worst or random traumatic event. The 
diagnostic interview showed good validity against the Clinician Administered PTSD Scale 
(Blake et al., 1995) as described elsewhere(Uddin et al., 2010). The Institutional Review 
Board of the University of Michigan reviewed and approved the study protocol. Incident 
cases (n=30) of PTSD were identified in either waves 2, 3, or 4 of DNHS data collection 
among individuals for whom blood samples were available at both the wave of first PTSD 
diagnosis and the immediately previous, pre-incident trauma wave. Non-PTSD controls 
(n=30) were matched to cases on the basis of age, sex, and number of traumatic event types. 
DNA samples were isolated from both pre- and post-trauma time points for both cases and 
controls. The time between pre- and post-trauma time points was approximately 1 year. 
Cases and controls had no history of PTSD prior to the post-trauma wave.
Methylation quantification by targeted bisulfite pyrosequencing
DNA Isolation—DNA was isolated from whole blood acquired via venipuncture when 
available from DNHS participants selected for inclusion in this study. Blood spots were used 
as an alternate source of whole blood-derived DNA when venipuncture samples were 
unavailable. The exact tissue type was shared between matched case-control pairs in all 
instances. Venipuncture- and bloodspot-derived whole blood represent the same tissue and 
therefore should not differ with respect to DNAm, as confirmed by numerous studies to date 
(Wong et al., 2008; Aberg et al., 2013; Hollegaard et al., 2013).
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Whole blood: DNA was isolated from whole blood using the QIAamp DNA Blood Mini 
Kit (Qiagen, Valencia, CA) and the QuickGene DNA Whole blood Kit S (Lifesciences, 
FujiFilm, Tokyo, Japan) using manufacturers’ recommended protocols.
Blood spots: DNA was isolated using the QIAamp DNA Micro Kit (Qiagen) using the 
manufacturer’s recommended protocol. For each sample, one 6mm punch was taken from 
dried blood spots using a disposable, sterile biopsy punch (Miltex, York, PA) within a sterile 
field and placed immediately into a sterile 1.7ml microcentrifuge tube. New gloves, biopsy 
punches, and sterile fields were utilized for each sample. Negative controls in the form of 
blank extractions were included with all DNA isolations.
Bisulfite conversion—For each sample, ~750ng of DNA was bisulfite converted using 
the EpiTect Bisulfite Kit (Qiagen) using the manufacturer’s recommended protocol. 
Negative controls in the form of bisulfite conversion of water were included with each 
bisulfite conversion.
Pyrosequencing—Assays to assess the methylation levels of CpG sites found in the 
DNMT1, DNMT3A, and DNMT3L and DNMT3B (see below for assay-specific details) were 
custom designed using the Pyromark Q24 Assay Design Software 2.0 (Qiagen). Targeted 
CpG sites were selected based on prior evidence(Uddin et al., 2010) of involvement in 
epigenetic regulation of PTSD risk (DNMT3B, DNMT3L) and to investigate whether 
longitudinal, PTSD-associated DNAm differences exist across DNA methyltransferase 
genes more broadly (DNMT1, DNMT3A, DNMT3B, and DNMT3L). Because the DNMT3B 
target CpG is located in a CpG island, our designed assay captures DNAm at 12 CpG sites 
in an approximately 70 base pair region of exon 1 (see DNMT3B assay section below for 
details). Single CpG sites were assessed at DNMT1, DNMT3A, and DNMT3L loci (see 
individual assay section below for details); these CpG sites did not fall into CpG islands. 
DNMT1, DNMT3A, and DNMT3L CpG sites and 2 DNMT3B CpG sites assessed are also 
found on the HM27 and HM450K methylation bead chips from Illumina (see below for 
actual HG19 nucleotide location). The capacity for each assay to capture DNAm levels 
ranging from 0–100% was validated using commercially available demethylated and highly 
methylated DNA at dilutions of 1:0 (unmethylated), 3:1, 1:1, 1:3, and 0:1 (highly 
methylated). PCR amplification of target sequences was performed on 20ng of bisulfite-
converted DNA samples using the PyroMark PCR kit (Qiagen). Bisulfite-converted, PCR-
amplified DNA was pyrosequenced on the Pyromark Q24 Pyrosequencer (Qiagen) using the 
manufacturer’s recommended protocol and default settings. All methylation analyses were 
conducted in triplicate with appropriate negative controls included at each of the following 
steps: DNA isolation, bisulfite conversion, PCR amplification, and pyrosequencing reaction.
Details of each custom assay are listed below.
DNMT1: PCR forward primer: TTTTTTTAGGTGTGATGGGGATAAAG
PCR reverse primer (biotinylated): CAAAAACTCTCACAAACCCTTAAA
PCR program (50 cycles):
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Initial 15 minutes at 95°C
Denaturation 30 seconds at 94°C
Annealing 30 seconds at 58°C
Extension 30 seconds at 72°C
Final 10 minutes at 72°C
Hold 4°C
Sequencing primer: GTGATGGGGATAAAGT
Target sequence: AGCGAGAAGCCCCCAAGGGTTTGTGAGA (CpG target in bold; 
hg19: chr19:10,305,909–10,305,936)
DNMT3A: PCR forward primer: GGTGGGAGGTTGAATGAAATGA
PCR reverse primer (biotinylated): AATACCCAACCCCAAATCCTAC
PCR program (50 cycles):
Initial 15 minutes at 95°C
Denaturation 30 seconds at 94°C
Annealing 30 seconds at 58°C
Extension 30 seconds at 72°C







TTG GGGCTGGGCACC (CpG target in bold; hg19: chr2:25,565,782–25,565,959)
DNMT3B: PCR forward primer: GGGGTTAAGTGGTTTAAGTAAAT
PCR reverse primer (biotinylated): CCTCCAAAAATCCCTAAAAAAAATCTCTCC
PCR program (45 cycles):
Initial 15 minutes at 95°C
Denaturation 30 seconds at 94°C
Annealing 30 seconds at 52°C
Extension 30 seconds at 72°C
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CAGCCAGCCCTGCGGCAGGTGAGCGCCCCGGGGCCC (CpG targets in bold; hg19: 
chr20:31,350,382–31,350,523)
DNMT3L: PCR forward primer: AGTTTTTTTTATTGGGGTAGTTAGG
PCR reverse primer (biotinylated): CTTAAAACCAAAAAACCACATTTTATTCA
PCR program (45 cycles):
Initial 15 minutes at 95°C
Denaturation 30 seconds at 94°C
Annealing 30 seconds at 50°C
Extension 30 seconds at 72°C
Final 10 minutes at 72°C
Hold 4°C
Sequencing primer: GATTTAGGGATAGAGAGGG
Target sequence: GCGGTAGGGAGTGGGAAATCTGAATAA (CpG target in bold; 
hg19: chr21:45,683,527–45,683,553)
To demonstrate the ability of our assays to resolve DNAm differences as small as reported, 
we computed intraclass correlation coefficients (ICC) between triplicate replicates for each 
assay. Average within-sample coefficient of variation was computed using a two-way mixed 
model, using an absolute agreement definition (Shrout and Fleiss, 1979), as implemented in 
SPSS. ICCs for the 15 total CpG sites assayed ranged from 0.703 to 0.937, with a mean ICC 
of 0.855 (standard deviation: 0.066). This strongly supports the conclusion that these assays 
are capable of consistently resolving small DNAm differences.
Transcription factor binding site prediction
Putative TFBS were identified that overlap target CpG sites using the 
MatInspector(Cartharius et al., 2005) tool from Genomatix, with default parameters. Input 
sequence included 200bp up and downstream of the CpG site. Only putative TFBS that 
directly overlapped CpG sites of interest were retained.
Statistical analyses
Statistical testing was performed using IBM SPSS Statistics for Windows, Version 21.0 
(IBM Corp., Armonk, NY). DNAm at DNMT3B CpG sites was treated on a regional and an 
individual CpG site basis, similar to previous work (Rusiecki et al., 2013). Regional values 
were calculated as the mean of 12 CpG sites. Paired-sample t-tests were used to test for 
differences in pre-trauma DNAm between cases and controls and to test for differences 
between pre- and post-trauma time points within cases and controls. Linear regression was 
used to test whether pre-trauma DNAm levels are predictive of post-trauma symptom 
severity (PTSS) changes. PTSS change was calculated as the difference between post-
trauma PTSS and pre-trauma PTSS. Analyses included severity scores of individual 
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symptom criteria (hyperarousal, avoidance, or intrusion symptoms) as well as a total 
severity score that is inclusive of each symptom subdomain. Regression models were 
adjusted for age, gender, and pre-trauma symptom severity. The contribution of pre-trauma 
DNAm to post-trauma PTSS change was tested via the change in R square values comparing 
full to reduced models. We present primary results uncorrected for multiple testing as is 
consistent with the current state of the science of DNAm variation in association with 
psychiatric endpoints(Perroud et al., 2011; Unternaehrer et al., 2012; Perroud et al., 2013; 
Rusiecki et al., 2013). In addition, to assess the extent to which our results may be 
attenuated by multiple hypothesis testing correction, we calculated stringent Bonferroni-
corrected significance values(Dunn, 1961) as well as false discovery rate (FDR) Q 
values(Benjamini, 1995). FDR has recently been utilized to correct multiple hypothesis 
testing in studies utilizing DNAm data, with user-defined Q-values ranging from 0.05 to 
0.2(Provencal et al., 2013; Zhao et al., 2013).
Results
PTSD cases and controls do not differ in age, gender, ethnicity, or pre-trauma symptom 
severity, including individual symptoms of intrusion, avoidance, and hyperarousal (Table 1).
Pre-trauma DNAm variation is associated with PTSD
PTSD-associated DNAm variation may both pre-exist trauma and be associated with post-
trauma PTSD outcome. To test for pre-existing protective/risk factors, pre-trauma DNAm at 
DNMT1, DNMT3A, DNMT3B, and DNMT3L loci was compared between trauma exposed 
individuals with vs. without PTSD. Pre-trauma DNAm was higher in cases compared with 
controls at a single DNMT3B CpG site (CpG 9) (Figure 1; t=2.250, 29 df, p=0.032); no 
difference in pre-trauma DNMT3B regional DNAm mean was observed (t=1.538, 29 df, 
p=0.135). We observed no pre-trauma differences between cases and controls at DNMT1 
(t=0.582, 29 df, p=0.565), DNMT3A (t=0.579, 29 df, p=0.567), and DNMT3L (t=1.386, 
29df, p=0.176) loci.
Pre-trauma DNAm variation predicts post-trauma changes in trauma symptom severity
To explore whether this PTSD-associated pre-trauma DNAm is predictive of trauma 
response, we performed linear regression analyses with pre-trauma DNAm of DNMT3B at 
CpG 9 and PTSS change as predictor and outcome variables, respectively. Controlling for 
age, gender, and pre-trauma symptom severity, pre-trauma DNAm of CpG 9 (Figure 2; 
unstandardized B=−2.318, SE=1.25 p=0.034) predicted post-trauma symptom severity 
change. In this model, only pre-trauma symptom severity and pre- trauma DNAm were 
significant predictor variables. DNMT3B CpG 9 DNAm explained approximately 6.8% of 
the variance in PTS severity change, as revealed by a comparison of the full and reduced 
models. The full model that included DNMT3B CpG 9 DNAm, age, gender, and pre-trauma 
symptom severity explained approximately 24% of the variance in post-trauma PTSS 
change (Adjusted R Square=0.242, p=0.005).
Because the relationship between pre-trauma DNAm and post-trauma changes in PTS 
symptom severity may be driven by distinct symptom subdomains (hyperarousal, avoidance, 
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and intrusion), we regressed separately each subdomain symptom severity change onto pre-
trauma DNAm, controlling for age, gender, and pre-trauma symptom severity of the relevant 
subdomain. Pre-trauma DNAm of DNMT3B CpG 9 (hyperarousal: p=0.249; avoidance: 
p=0.137; intrusion: p=0.071) did not predict change in subdomain symptom severity.
Trauma induces PTSD-associated DNAm modifications
DNAm differences may arise following trauma and be associated with PTSD development. 
To test this, we compared pre-trauma DNAm with post-trauma DNAm within PTSD cases 
and within trauma-exposed, healthy controls. Both PTSD-associated and PTSD-independent 
changes in DNAm following trauma were observed at DNMT loci (Figure 3). DNMT1 
DNAm increased (Figure 3A; t=3.887, 29 df, p=0.001) following trauma in the PTSD group, 
but not the control group (t=1.903, 29 df, p=0.067). At DNMT3A (Figure 3B) and DNMT3B 
(Figure 3C) loci, DNAm increased following trauma in both PTSD case (DNMT3A: t=2.806, 
29 df, p=0.009; DNMT3B: t=4.286, 29 df, p<0.001) and control (DNMT3A: t=3.421, 29 df, 
p=0.002; DNMT3B: t=3.938, 29 df, p<0.001) groups. No change was observed in DNMT3L 
(Figure 3D) DNAm in either cases (t=1.551, 29 df, p=0.132) or controls (t=1.146, 29 df, 
p=0.261). Table 3 presents a summary including uncorrected p values, Bonferroni-corrected 
p values, and FDR values, as well as accompanying effect sizes, of our results described 
above.
Transcription factor binding site prediction
DNAm is associated with gene expression. One mechanism by which increased DNAm can 
lead to decreased gene expression is by affecting the binding of trans-activating factors to 
cis-regulatory elements. To contextualize our DNAm findings, we used bioinformatic 
methods to identify putative TFBS that overlap CpG sites showing PTSD-associated DNAm 
differences. In total, we identified 24 putative TFBS, including 2, 3, 14, and 5 that overlap 
DNMT1, DNMT3A, DNMT3B, and DNMT3L CpG target sites, respectively (Table 2). 
Notable among these 24 TFBS are those that overlap with CpG sites at which we identified 
PTSD-associated differential methylation (2 overlap the DNMT1 CpG; 3 overlap DNMT3B 
CpG 9). Binding sites for heat shock factor 1 and E2F-4/DP-2 heterodimeric complex were 
identified to overlap with the DNMT1 CpG site at which an increase in DNAm was observed 
in PTSD cases, but not controls. Overlapping with DNMT3B CpG site 9, at which increased 
pre-trauma DNAm was associated with PTSD development and predictive of worsening of 
PTSS, we identified binding sites for Human motif ten element, ZF5 POZ domain zinc 
finger, and the insulator protein CTCF.
Discussion
Our data represent preliminary findings suggesting that pre-trauma DNAm states and post-
trauma DNAm modifications differ between those who develop PTSD following trauma and 
those who display resiliency. While baseline PTS symptoms did not differ between cases 
and controls, baseline DNAm at a DNMT3B CpG site was higher in resilient individuals 
compared to those who eventually developed PTSD. Additionally, longitudinal change in 
DNAm at a DNMT1 CpG site was associated with PTSD, with an increase in DNAm being 
observed in those with PTSD but not controls. Finally, increases in DNAm were observed 
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following trauma at DNMT3A and DNMT3B loci that were independent of PTSD outcome, 
being observed in both PTSD cases and trauma-exposed controls. Although some of these 
results were attenuated following correction for multiple hypothesis testing, our findings 
suggest that epigenetic variation plays a complex regulatory role in PTSD risk and etiology.
One way in which DNAm may regulate gene transcription is by altering the strength and 
occupancy of transcription factor binding (Weaver et al., 2004). To provide insight into 
potential functional consequences of the observed PTSD-associated differences, we 
conducted a secondary analysis of TFBS overlapping the distinguishing CpG sites. Among 
the sites identified was a binding site for CTCF, a transcription factor known to be involved 
in chromatin remodeling(Barkess and West, 2012). We identified this binding site 
overlapping with DNMT3B CpG site 9, at which higher DNAm was identified as a 
protective/risk factor for PTSD and symptom severity change following trauma exposure. 
Differential methylation at this site is particularly compelling as a determinant of PTSD risk, 
given that DNAm at CTCF binding sites has been shown to significantly affect CTCF 
occupancy(Wang et al., 2012) and downstream levels of gene transcription(Renaud et al., 
2007). Due to the nature of our samples, we are unable to test directly whether DNAm at 
these identified TFBS influences gene expression. Where available, we have utilized 
ENCODE data(Consortium, 2011) to provide evidence for or against transcription factor 
binding at the PTSD-associated sites in blood-derived cell types. Among the TFBS 
identified that overlap PTSD-associated CpG sites (DNMT1 and DNMT3B CpG 9), 
ENCODE data includes binding of CTCF and E2F4. ENCODE data supports the binding of 
CTCF to DNMT3B in blood tissue (specifically b-lymphocyte cell lines: GM12864 and 
GM12874), but does not support the binding of E2F4 to DNMT1. This supports the potential 
functionality of observed DNAm differences at DNMT3B CpG 9 in pre-trauma samples in 
cases vs. controls.
DNMTs have been previously implicated in PTSD, anxiety, and fear conditioning. In suicide 
completers relative to controls, DNMT3B was upregulated in the frontopolar cortex, 
hypothalamus, and dorsal vagal complex and down regulated, along with DNMT1, in the 
hippocampus(Poulter et al., 2008). Additionally, de novo methyltransferases have been 
shown to be upregulated during contextual fear conditioning, also in the hippocampus 
(Miller and Sweatt, 2007); DNMTs are required for fear conditioning and memory 
consolidation as demonstrated, respectively, by administration of DNMT inhibitors (Miller 
and Sweatt, 2007) and the creation of mice with the combined knockout of DNMT1 and 
DNMT3A(Feng et al., 2010). Our results thus add to the growing evidence implicating 
DNMTs in phenotypes of relevance to PTSD, and of psychiatric phenotypes more broadly.
The expression of DNMTs at the mRNA(Goto et al., 1994; Veldic et al., 2004; Kang et al., 
2011; Sterner et al., 2012) and protein(Inano et al., 2000; Feng et al., 2005; Veldic et al., 
2005) levels in post-mitotic neurons of the central nervous system suggests that they are 
involved in methyltransferase activity that persists into adulthood and that is unrelated to 
DNA replication(Goto et al., 1994). Indeed, previous work has identified DNMT1 protein 
expression in multiple brain regions in rodents (e.g. cortex, cerebellum(Inano et al., 2000)), 
as well as in specific cortical regions in adult humans (e.g. Broadmann’s Area 9(Veldic et 
al., 2005)). Furthermore, recent work suggests that our epigenetic findings in peripheral 
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blood may be relevant to brain tissue: environmental exposures such as trauma have been 
shown to induce parallel epigenetic modifications in peripheral blood and brain (McGowan 
et al., 2011; Klengel et al., 2013). Although the current study, based on living participants 
drawn from a population-based cohort, precludes such work, future research is needed to 
address whether the epigenetic determinants of risk observed here in peripheral blood-
derived DNA is also found in brain-derived DNA.
Importantly, this study adds to emerging work utilizing a longitudinal study design capable 
of measuring biological markers prior to disease onset as well as change between pre-
disease and post-disease time points(Nieratschker et al., 2012; Rusiecki et al., 2012; Perroud 
et al., 2013; Rusiecki et al., 2013). Existing longitudinal studies have documented the 
importance of DNAm to mental health disorder risk, including differential change in DNAm 
of BDNF among individuals with vs. without borderline personality disorder(Perroud et al., 
2013), increased DAT (SLC6A3) DNAm with age that may be driven by alcohol 
dependence(Nieratschker et al., 2012), and increasing SERT DNAm associated with 
bullying(Ouellet-Morin et al., 2013). Most relevant to the present study is work by Rusiecki 
et al.(Rusiecki et al., 2012) which provides evidence for increased global DNAm in controls, 
but not cases following trauma exposure, suggesting that resiliency is associated with 
increased global DNAm, potentially mediated by increased activity and expression of 
DNMTs. Indeed, our data presented here is consistent with this scenario, as DNAm of 
DNMT1 was observed to increase following trauma in cases, but not controls. In contrast, 
however, we observed an increase in DNMT3B DNAm following trauma in both cases and 
controls, and a pre-trauma association between higher DNAm pre-trauma and resiliency 
post-trauma. The presence of a CTCF binding site opens the possibility that increased 
DNAm at this locus is associated with increased gene expression because CTCF can act as 
either a transcriptional activator or repressor(Phillips and Corces, 2009), with strength of 
DNA binding inversely correlated with local DNAm(Barkess and West, 2012). If binding of 
CTCF to the DNMT3B locus results in transcriptional repression, then increased DNAm, and 
concurrent decreased CTCF binding, would be associated with increased, not decreased, 
gene expression. If true, this would put these findings in line with the previously published, 
longitudinal, trauma-associated epigenetic data: decreased DNAm in pre-trauma PTSD 
cases would result in tighter CTCF binding and reduced DNMT3B transcription and lower 
global DNAm levels, as reported by Ruisecki and colleagues(Rusiecki et al., 2012). 
Although DNMT1 is typically thought to maintain DNAm in adult tissues, evidence 
suggests that DNMT1 and DNMT3B cooperatively maintain DNAm, with one or the other, 
but not both, required for global DNAm(Rhee et al., 2002). More broadly, our data adds to 
the emerging evidence that longitudinal DNAm changes may contribute to the etiology of 
mental illness and can be taken as a proof of principle that locus-specific epigenetic 
variability both pre-exist and arise following disease-onset in biologically meaningful ways.
While our study is one of the first of its kind to compare pre- and post-trauma DNAm levels 
with regard to the development of PTSD, there is a minimum of four study limitations that 
should be kept in mind when interpreting our results. First, it is important to recognize that 
the epidemiological nature of our cohort precludes sample collection with a well-controlled 
experimental time course; times between pre-trauma data collection, trauma exposure, and 
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post-trauma data collection differed between each test subject. As such, we are unable to 
resolve whether observed PTSD-associated post-trauma DNAm changes precede PTSD-
development (i.e. occurred within the first four weeks following trauma). As DNMTs are 
involved in the global regulation of DNAm, it is tempting to conclude from our data that 
observed changes in DNMT DNAm are an upstream process of PTSD development, thereby 
having the potential to help explain differences in DNAm epigenome-wide reported 
elsewhere(Uddin et al., 2010; Smith et al., 2011; Rusiecki et al., 2012). However, it is also 
possible that the observed PTSD-associated DNAm changes are downstream effects of 
PTSD development, with no or little involvement in epigenetic modifications across the 
epigenome. Second, the nature of the epidemiological samples collected precluded the 
assessment of pre- and post-trauma gene expression differences and changes, as well as any 
analysis of blood cell composition. Third, the DNAm differences and effect sizes reported 
here are small; however, they are consistent with published work showing functional effects 
of DNAm variation(Tyrka et al., 2012). High intraclass correlation coefficients between 
experimental replicates for each of our assays increases confidence of the validity of 
observed DNAm differences. Indeed, our sample size and observed effect sizes are 
consistent with published work in the field(Perroud et al., 2011; Byrne et al., 2013). Fourth, 
our results across the multiple CpG sites within DNMT3B are not corrected for multiple 
testing. Although this is consistent with the current state of the science of DNAm variation 
in association with psychiatric endpoints(Perroud et al., 2011; Unternaehrer et al., 2012; 
Perroud et al., 2013; Rusiecki et al., 2013), we do report corrected results (Table 3) to assess 
the degree to which our findings might be attenuated by multiple hypothesis test correction. 
Accepting a stringent FDR of 0.05 requires that we reject several findings reported as 
significant in our study, notably pre-trauma DNAm differences between cases and controls 
at DNMT3B CpG 9. However, it also means that a significant association between DNAm 
and PTSD emerges as a result of correction, as a significant change in DNAm at DNMT3A 
following trauma is only seen in controls at this stringent FDR cutoff and would therefore be 
suggestive of a resiliency-associated change in DNAm (Table 3). While we have chosen to 
utilize a stringent FDR cut-off of 0.05, other DNAm analyses have accepted a cut-off as 
high as 0.20(Provencal et al., 2013). Overall, we stress the preliminary nature of these 
findings—both uncorrected and corrected for multiple hypothesis testing—and the 
importance of replication in an independent cohort.
Individuals exposed to trauma differ in their risk for subsequent PTSD. Our data suggest that 
variation in pre-trauma DNAm and post-trauma DNAm change may be part of the molecular 
underpinnings of PTSD risk and resiliency. Future research is needed to determine if the 
DNAm variation observed here is associated with functional changes that affect the long-
term biology of individuals exposed to trauma. The identification of risk markers, including 
epigenetic markers, is an important step to understanding the biological underpinnings of 
PTSD risk and may lead to the development of tools to identify those individuals most at 
risk of developing PTSD as well as to develop evidence-based interventions.
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Pre-trauma “DNA methyltransferase 3B” (DNMT3B) DNA methylation (DNAm) is 
significantly higher in trauma-exposed controls compared to posttraumatic stress disorder 
(PTSD) cases at CpG 9. Pre-trauma DNAm did not differ between cases and controls at the 
other 11 DNMT3B CpG sites assessed. Light gray bars indicate mean DNAm of controls. 
Dark gray bars indicate mean DNAm of PTSD cases. Error bars represent standard error of 
the mean. Difference between controls and cases was tested by paired-sample t-tests (N = 
60; 30 cases and 30 matched controls). *: p<0.05.
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Linear regression model of symptom severity (PTSS) change post-trauma and pre-trauma 
“DNA methyltransferase 3B” (DNMT3B) CpG 9 DNA methylation (DNAm), adjusting for 
age, gender, and pre-trauma symptom severity (N=60). Only pre-trauma PTSS and DNAm 
were significant variables in this model. Error bar plots represent the mean plus/minus the 
95% confidence intervals. Differences between posttraumatic stress disorder cases and 
trauma-exposed controls were tested by paired-sample t-tests (N = 60; 30 PTSD cases and 
30 matched controls). *: p<0.05.
Sipahi et al. Page 19














Longitudinal DNA methylation (DNAm) modifications of DNA methyltransferase (DNMT) 
loci in response to trauma in posttraumatic stress disorder (PTSD) cases and trauma-exposed 
controls. DNMT3B (region) represents the mean of 12 CpG sites. Differences between 
PTSD cases and trauma-exposed controls were tested by paired-sample t-tests (N = 60; 30 
PTSD cases and 30 matched controls). Error bars represent standard error of the mean. *: 
p<0.05; **:p<0.01; ***:p<0.001.
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Table 2
Putative transcription factor binding sites overlap DNA methyltransferase (DNMT) CpG sites of interest. V$ 
matrix families indicate Genomatix-annotated transcription factor binding site matrix families. DNMT3B CpG 
sites are described in the Methods.
Gene Matrix Family Matrix Information Core similarity DNMT3B CpG overlap
DNMT1 V$HEAT Heat shock factor 1 1.000 -
V$E2FF E2F-4/DP-2 heterodimeric complex 0.847 -
DNMT3A V$SP1F TGFbeta-inducible early gene (TIEG)/Early growth response 
gene alpha (EGRalpha)
0.750 -
V$SP1F Stimulating protein 1, ubiquitous zinc finger transcription factor 1.000 -
V$EGRF EGR1, early growth response 1 0.802 -
V$GCMF Glial cells missing homolog 1, chorion-specific transcription 
factor GCMa
1.000 -
V$KLFS Kidney-enriched kruppel-like factor, KLF15 1.000 -
DNMT3B O$MTEN Human motif ten element 0.839 1, 2, 3, 4, 5
V$PAX5 PAX5 paired domain protein 0.789 1, 2, 3, 4, 5, 6, 7
V$E2FF E2F transcription factor 3 (secondary DNA binding preference) 1.000 2, 3, 4, 5
V$E2FF E2F transcription factor 3 (secondary DNA binding preference) 1.000 2, 3, 4, 5, 6, 7
V$ETSF Ets variant 4 1.000 3, 4, 5, 6, 7
O$MTEN Human motif ten element 0.961 7, 8, 9
V$ZF5F ZF5 POZ domain zinc finger, zinc finger protein 161 (secondary 
DNA binding preference)
0.775 8, 9, 10
V$CTCF Insulator protein CTCF (CCCTC-binding factor) 0.818 9, 10, 11, 12
V$HDBP Huntington’s disease gene regulatory region-binding protein 1 
and 2 (SLC2A4 regulator and papillomavirus binding factor)
1.000 10, 11, 12
V$EGRF Collagen krox protein (zinc finger protein 67-zfp67) 1.000 11, 12
V$PLAG Pleomorphic adenoma gene (PLAG) 1, a developmentally 
regulated C2H2 zinc finger protein
0.958 12
V$ZF02 Transcriptional repressor, binds to elements found 
predominantly in genes that participate in lipid metabolism
0.776 12
DNMT3L V$KLFS Basic transcription element (BTE) binding protein, BTEB3, 
FKLF-2
1.000 -
V$SP1F Stimulating protein 1, ubiquitous zinc finger transcription factor 1.000 -
V$MYBL C-Myb, important in hematopoesis, cellular equivalent to avian 
myoblastosis virus oncogene v-myb
0.797 -
V$GLIF Zinc finger transcription factor, Zic family member 2 (odd-
paired homolog, Drosophila)
1.000 -
V$CP2F LBP-1c (leader-binding protein-1c), LSF (late SV40 factor, 
CP2, SEF (SAA3 enhancer factor)
0.875 -
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